RXi Pharmaceuticals Corp (NASDAQ:RXII)

RXi Pharmaceuticals Corp (NASDAQ:RXII) To Make Presentation

RXi Pharmaceuticals Corp (NASDAQ:RXII)

RXi Pharmaceuticals Corp (NASDAQ:RXII) has announced that its research vice president, Karen Bulock, will make a presentation at this year’s Annual BIO Investor Forum – taking place in San Francisco, California. At the forum, Bulock will talk about the RNAi platform which is self-delivering as well as demonstrate how it can be applied in the treatment of cancer using cell-based immunotherapies.

The expected attendees of the investor conference include the industry executives of various biotech and pharmaceutical companies, research analyst, public investors, and private equity investors. The event will also be webcast.

RXi Pharmaceuticals Corp (NASDAQ:RXII)

September presentations

Last month RXi Pharmaceuticals Corp (NASDAQ:RXII) made a series of presentations at various events. This included a presentation made by the company’s intellectual property and business development director, James Cardia, at the 10th Annual International Partnering Conference which took place in Boston, Massachusetts.

At the event Cardia gave a corporate overview which included the RNA therapeutic platform which is self-delivering. Cardia also talked about the company’s ongoing clinical and research programs especially in the areas of ophthalmology, dermatology and immunotherapy. The event had drawn leaders from various sectors including pharmaceutical, finance and biotech.

Another presentation that was made last month was by the chief development officer of RXi Pharmaceuticals Corp (NASDAQ:RXII), Gerrit Dispersyn. This was at the Ladenburg Thalmann Healthcare Conference which took place in New York City. Dispersyn’s presentation revolved around RNAi which is a self-delivering platform and applicable in various therapeutic areas. His presentation also touched on various RXi programs including ophthalmology, dermatology and immune-oncology.

RXi Executive departure

Last month also saw the RXi’s chief business officer, Alexey Eliseev, leave the company. Eliseev had joined RXi at the beginning of the year after RXi acquired Mirimmune, a privately-held firm which develops therapeutics used in the treatment of cancer.

“The Company would like to thank Dr. Eliseev for his support in integrating MirImmune into our Company’s day-to-day activities, and for providing RXi exposure to some of the key players in this new and exciting space,” RXi Pharmaceuticals Corp (NASDAQ:RXII)’s chief executive officer and president, Dr. Geert Cauwenbergh, said after the departure of Eliseev.

While at RXi the group that was led by Cardia was involved in discovering and optimizing rxRNAs which are self-delivering. Cardia’s group was also responsible for the characterization and development of RXI-109, an anti-fibrotic agent which is currently being tested as a therapy for retinal and dermal scarring.

Following Eliseev’s exit, Cardia took over the business development and partnering responsibilities. Eliseev obtained a chemistry Ph.D from Boston College and received his postdoctoral training at Harvard University.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RXII Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.